EUVIMEDEUVIMED entdecken
Leserbrief

Response to V. Martín‐Dominguez Et Al.: Re‐Evaluating the Diagnostic Approach to Lactose Malabsorption

C Hermida Díaz, B Pascual Miguel, C Ferreras Puente iD

Neurogastroenterology & Motility · 2025

DOI: 10.1111/nmo.70217 ↗

Kurz gefasst

Leserbrief in der Zeitschrift Neurogastroenterology & Motility, 2025. Verfasst von C Hermida Díaz und 2 weiteren Autor:innen. Beteiligte Einrichtung: Research and Innovation Department, Venter Pharma SL, Madrid, Spain. Hauptthemen laut MEDLINE: Lactose Intolerance, Genetic Testing. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 33 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The article by Martín‐Domínguez V et al. proposes genetic testing as the first diagnostic test for lactose malabsorption, given its high concordance with the lactose breath test (LBT). We think that conceptual and methodological inconsistencies undermine this conclusion.

Methods

The genetic test, LBT, and Gaxilose test measure different physiological aspects such as genetic predisposition, lactose malabsorption, and lactase enzymatic activity, respectively, so the three tests cannot be used interchangeably. Diagnostic bias is introduced by the study's limited use of biopsy confirmation, disregard for secondary hypolactasia, and reliance on genotype as a reference standard.

Results

Additionally, the clinical validity of the results is compromised by the high variability in genetic polymorphisms across populations, unreported comorbidities like SIBO or IBS, and dubious symptom assessment during testing. Evidence from multicenter studies demonstrates that the Gaxilose test offers high sensitivity and specificity and is well tolerated.

Conclusions

We conclude that genetic testing alone cannot replace functional or structural assessments and warn that the study's conclusions may lead to misleading diagnostic recommendations in real‐world clinical practice.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lactose IntoleranceGenetic TestingHumansBreath TestsLactase

Stichwörter der Autor:innen

LBTbiopsygaxilosegenetic testlactose malabsortionright diagnosticsecondary hypolactasia

Substanzen

Lactase

Autor:innen und Institutionen

  • Research and Innovation Department, Venter Pharma SL, Madrid, Spain.

ORCID-Profile: C Ferreras Puente

Zitieren

APA

Hermida Díaz, C., Pascual Miguel, B., & Ferreras Puente, C. (2025). Response to V. Martín‐Dominguez Et Al.: Re‐Evaluating the Diagnostic Approach to Lactose Malabsorption. Neurogastroenterology & Motility. https://doi.org/10.1111/nmo.70217

Vancouver

Hermida Díaz C, Pascual Miguel B, Ferreras Puente C. Response to V. Martín‐Dominguez Et Al.: Re‐Evaluating the Diagnostic Approach to Lactose Malabsorption. Neurogastroenterology & Motility. 2025. doi:10.1111/nmo.70217

BibTeX
@article{HermidaDaz2025,
  author = {Hermida Díaz, C and Pascual Miguel, B and Ferreras Puente, C},
  title = {Response to V. Martín‐Dominguez Et Al.: Re‐Evaluating the Diagnostic Approach to Lactose Malabsorption},
  journal = {Neurogastroenterology & Motility},
  year = {2025},
  doi = {10.1111/nmo.70217}
}
Kostenlos starten →